This paper describes the active power and frequencycontrol principles of multiple distributed generators (DGs) in a microgrid. Microgrids have two operating modes: 1) a grid-connected mode and 2) an islanded mode. During islanded operation, one DG unit should share output generation power with other units in exact accordance with the load. Two different options for controlling the active power of DGs are introduced and analyzed: 1) unit outputpower control (UPC) and 2) feeder flow control (FFC). Taking into account the control mode and the configuration of the DGs, we investigate power-sharing principles among multiple DGs under various system conditions: 1) load variation during grid-connected operation, 2) load variation during islanded operation, and 3) loss of mains (disconnected from the main grid). Based on the analysis, the FFC mode is advantageous to the main grid and the microgrid itself under load variation conditions. However, when the microgrid is islanded, the FFC control mode is limited by the existing droop controller. Therefore, we propose an algorithm to modify the droop constant of the FFC-mode DGs to ensure proper power sharing among DGs. The principles and the proposed algorithm are verified by PSCAD simulation.

IMPORTANCE Ovarian cancer has the highest mortality rate among gynecologic malignant tumors. Data are lacking on the survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with ovarian cancer who underwent primary or interval cytoreductive surgery.OBJECTIVE To assess the clinical benefit of HIPEC after primary or interval maximal cytoreductive surgery in women with stage III or IV primary advanced ovarian cancer. DESIGN, SETTING, AND PARTICIPANTSIn this single-blind randomized clinical trial performed at 2 institutions in South Korea from March 2, 2010, to January 22, 2016, a total of 184 patients with stage III or IV ovarian cancer with residual tumor size less than 1 cm were randomized (1:1) to a HIPEC (41.5 °C, 75 mg/m 2 of cisplatin, 90 minutes) or control group. The primary end point was progression-free survival. Overall survival and adverse events were key secondary end points. The date of the last follow-up was January 10, 2020, and the data were locked on February 17, 2020. EXPOSURES Hyperthermic intraperitoneal chemotherapy after cytoreductive surgery.MAIN OUTCOMES AND MEASURES Progression-free and overall survival. RESULTSOf the 184 Korean women who underwent randomization, 92 were randomized to the HIPEC group (median age, 52.0 years; IQR, 46.0-59.5 years) and 92 to the control group (median age, 53.5 years; IQR, 47.5-61.0 years). After a median follow-up of 69.4 months (IQR, 54.4-86.3 months), median progression-free survival was 18.8 months (IQR, 13.0-43.2 months) in the control group and 19.8 months (IQR, 13.7-55.4 months) in the HIPEC group (P = .43), and median overall survival was 61.3 months (IQR, 34.3 months to not reported) in the control group and 69.5 months (IQR, 45.6 months to not reported) in the HIPEC group (P = .52). In the subgroup of interval cytoreductive surgery after neoadjuvant chemotherapy, the median progression-free survival was 15.4 months (IQR, 10.6-21.1 months) in the control group and 17.4 months (IQR, in the HIPEC group (hazard ratio for disease progression or death, 0.60; 95% CI, 0.37-0.99; P = .04), and the median overall survival was 48.2 months (IQR, 33.8-61.3 months) in the control group and 61.8 months (IQR, 46.7 months to not reported) in the HIPEC group (hazard ratio, 0.53; 95% CI, 0.29-0.96; P = .04). In the subgroup of primary cytoreductive surgery, median progression-free survival was 29.7 (IQR, 17.2-90.1 months) in the control group and 23.9 months (IQR, 12.3-71.5 months) in the HIPEC group, and the median overall survival was not reached in the control group and 71.3 months (IQR, 45.6 months to not reported) in the HIPEC group. CONCLUSIONS AND RELEVANCEThe addition of HIPEC to cytoreductive surgery did not improve progression-free and overall survival in patients with advanced epithelial ovarian cancer. Although the results are from a subgroup analysis, the addition of HIPEC to interval cytoreductive surgery provided an improvement of progression-free and overall survival.

In this paper, an effective fault location algorithm and intelligent fault diagnosis scheme are proposed. The proposed scheme first identifies fault locations using an iterative estimation of load and fault current at each line section. Then an actual location is identified, applying the current pattern matching rules. If necessary, comparison of the interrupted load with the actual load follows and generates the final diagnosis decision. Effect of load uncertainty and fault resistance has been carefully investigated through simulation results that turns out to be very satisfactory.

No abstract

This paper proposes a three-level discrete Fourier transform (DFT) method to provide an accurate estimate of power system frequency in real time. The first level decomposes a power system signal into two orthogonal cosine-and sine-filtered signals. The second and third levels are used to determine the amplitude ratio of the cosine-and sine-filtered signals without encountering the zero-crossing problem and with an increase in ability to suppress harmonics and inter-harmonics. The performance of the three-level DFT method is evaluated using computer-simulated signals with harmonics and inter-harmonics. The three-level DFT method is also implemented on a digital signal processor (DSP)-based hardware prototype, and its performance in the hardware implementation is evaluated using a real-time digital simulator (RTDS). The evaluation results show that the three-level DFT method can achieve real-time estimation of power system frequency with satisfactory performance.